Skip to main content
Premium Trial:

Request an Annual Quote

BG Medicine Receives Notice of Non-compliance from Nasdaq

NEW YORK(GenomeWeb) – BG Medicine said after the close of the market on Friday that it has received a notice of non-compliance from Nasdaq indicating that the company's stock is subject to delisting unless it makes a timely request for a hearing before the Nasdaq Listing Qualifications Panel. 

BG Medicine said that it will request a hearing at which it will present its plan to regain and maintain compliance with the applicable listing requirements. The company's stock will continue to trade on Nasdaq pending the hearing.

BG Medicine is in non-compliance with the requirement that its stock have a minimum $1 closing bid for 30 consecutive business days. The company received a warning from Nasdaq in September regarding its non-compliance and was given until March 4, 2015 to achieve compliance.

BG Medicine is also in danger of being delisted from the exchange for not being in compliance with a listing requirement calling for minimum of $2.5 million in stockholders' equity or a market capitalization of at least $35 million. The company has until May 19 to achieve compliance with this requirement.

In morning trading on Monday, shares of BG Medicine were down more than 8 percent at $.81.  

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more